**[387] THE TARGT EX-VIVO GENE THERAPY PLATFORM**

**Shany Blum1, Nir Shapir1, Reem Miari1, Garry Neil2, 1 Medgenics Medical Israel Ltd., 2 Medgenics Inc.**

* **Investment Rational**

Medgenics is focused on fulfilling the promise of genomic medicine to improve the lives of patients with rare and difficult-to-treat diseases. The company's core capabilities, including its internal R&D and ongoing sponsored research and licensing agreements endow Medgenics with deep insight into the underlying genetic pathway of disease and guides us in pursuing solutions for patients with life-altering diseases.

* **Business Strategy**

Medgenics utilizes its collaboration with the Children Hospital of Philadelphia to identify rare and orphan genetic conditions with high unmet need and tailoring the appropriate therapy either using the company's core gene therapy technology or other licensed technologies.

* **Core Technology**
The company's core technology is the TARGT™ system (Transduced Autologous Restorative Gene Therapy), an ex-vivo gene therapy, providing autologous, continuous protein or peptide therapies using a biologic implant (a "living drug") from the patient's own skin.
* **Product Profile/Pipeline**
The TARGT™ system was first developed to secrete human erythropoietin. It was tested in clinical trials in dialysis patients, showing impressive results by stabilizing patients' hemoglobin level in the desired range per clinical guidelines for several months without the need for erythropoietin injections or blood transfusions.
* **What's Next?**
Medgenics is translating the great promise of the TARGT™ platform into a pipeline of products secreting monoclonal antibodies and enzymes in a variety of clinical indications.